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ABSTRACT

ARTICLE HISTORY

Surgical removal of the intestine, lifesaving in catastrophic gastrointestinal disorders of infancy, can
result in a form of intestinal failure known as short bowel syndrome (SBS). Bloodstream infections
(BSIs) are a major challenge in pediatric SBS management. BSIs require frequent antibiotic therapy,
with ill-defined consequences for the gut microbiome and childhood health. Here, we combine
serial stool collection, shotgun metagenomic sequencing, multivariate statistics and genomeresolved strain-tracking in a cohort of 19 patients with surgically-induced SBS to show that
antibiotic-driven intestinal dysbiosis in SBS enriches for persistent intestinal colonization with BSI
causative pathogens in SBS. Comparing the gut microbiome composition of SBS patients over the
first 4 years of life to 19 age-matched term and 18 preterm controls, we find that SBS gut microbiota
diversity and composition was persistently altered compared to controls. Commensals including
Ruminococcus, Bifidobacterium, Eubacterium, and Clostridium species were depleted in SBS, while
pathobionts (Enterococcus) were enriched. Integrating clinical covariates with gut microbiome
composition in pediatric SBS, we identified dietary and antibiotic exposures as the main drivers
of these alterations. Moreover, antibiotic resistance genes, specifically broad-spectrum efflux
pumps, were at a higher abundance in SBS, while putatively beneficial microbiota functions,
including amino acid and vitamin biosynthesis, were depleted. Moreover, using strain-tracking
we found that the SBS gut microbiome harbors BSI causing pathogens, which can persist intestin
ally throughout the first years of life. The association between antibiotic-driven gut dysbiosis and
enrichment of intestinal pathobionts isolated from BSI suggests that antibiotic treatment may
predispose SBS patients to infection. Persistence of pathobionts and depletion of beneficial micro
biota and functionalities in SBS highlights the need for microbiota-targeted interventions to
prevent infection and facilitate intestinal adaptation.
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Introduction

Surgical removal of the intestine is often neces
sary to treat gastrointestinal disorders such as
necrotizing enterocolitis, volvulus, gastroschisis,
and intestinal atresia.1 Extensive intestinal loss
may result in a form of intestinal failure known
as short bowel syndrome (SBS).2,3 In SBS,
reduced intestinal surface area is inadequate for
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normal nutrients, electrolytes, and fluid absorp
tion. As a result, patients require sustained par
enteral nutrition (PN) to support growth and
development.4 While lifesaving, prolonged PN is
associated with SBS-related morbidity and mor
tality, most notably bloodstream infections
(BSIs)1,5 and PN-associated liver disease
(PNALD).2,6 Further, SBS patients frequently
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develop increased bowel caliber and reduced
peristalsis resulting in small bowel bacterial over
growth (SBBO).7 Increased gut-derived bacterial
burden in the context of SBBO is implicated in
contributing to PNALD.8 Retrospective studies of
BSIs in SBS patients have further implicated
common constituents of the intestinal flora.9 As
a result, SBS patients are frequently exposed to
multiple courses of oral and intravenous antibio
tics to prevent and treat SBBO, PNALD, and BSI.
Diversity and richness of the gut microbiota (GM)
in children with SBS are lower than corresponding
indices in age-matched controls.10–12 The SBS GM is
characterized by increased abundance of
Enterobacteriaceae and depletion of short-chain fatty
acid-producing obligate anaerobes,10,11,13 an imbal
ance that has been associated with poor growth.14
While prior work has identified the GM as
a determinant of successful weaning from PN, con
clusions are limited by sample size, lack of suitable
age-matched preterm and term controls, and crosssectional nature of comparisons. Also, most studies
have relied on 16S ribosomal RNA (rRNA) gene
sequencing, which does not assess the functional con
sequences of microbial dysbiosis and hinders identi
fication of the main drivers of SBS GM development.
Genome-resolved metagenomic profiling in long
itudinal studies offers deeper insights into the longterm functional microbiome consequences asso
ciated with SBS and can inform nutrition manage
ment. Time-series study of the GM is critical, as
children with SBS are frequently exposed to broadspectrum antibiotics throughout childhood.15 Each
exposure can abruptly and persistently alter the GM,
enrich the pool of antibiotic resistance genes
(ARGs), and select for pathobionts,16,17 which are
constituents of the microbiota with increased patho
genic potential. Additionally, altered gut physiology
may predispose to pathogen translocation into cir
culation, resulting in BSI. Indeed, the gut has been
identified as a source for bacterial infections in pre
mature infants,18 hematopoietic stem cell transplant
patients,19 and patients who received fecal micro
biota transplants.20 However, the risk associated
with gastrointestinal pathobiont colonization and
antibiotic exposure in SBS patients is unclear.
Here, we use multivariate statistics and deep
metagenomic sequencing to show that repeated
antibiotic exposures in early life hinder recovery

of gut microbiota diversity and durably enrich for
ARGs and pathobionts, while depleting beneficial
commensals and microbiota functions. We
hypothesized that intestinal pathobiont enrichment
in SBS may serve as a source for BSI. Pairing deep
metagenomic sequencing of the intestinal micro
biota with isolate sequencing of BSI isolates, we
provide genome-resolved evidence that gutresiding pathobionts cause repeated BSIs in SBS
patients throughout the first 4 years of life.
Results
SBS patient cohort and controls

To test the hypothesis that taxa and functions of the
GM vary from normal development throughout
early life in SBS, we first analyzed 159 stools, col
lected over the first four years of life from 19 chil
dren with SBS (n = 19) and 37 age-matched term
(n = 19) and preterm (n = 18) controls using whole
metagenome shotgun sequencing (Table 1).
Preterm infant samples included in this study
were collected during the first 2 years of life. One
SBS participant had a higher age at sampling com
pared to all other infants (SBS 05) and was therefore
excluded from comparative analysis.
The intestinal microbiota in SBS are persistently
altered throughout early life

Longitudinal GLMMs for microbiota taxonomic
alpha (Shannon) diversity demonstrated that chil
dren with SBS had lower alpha diversity than did
term children throughout the first four years of life
(n = 104 samples, P = 1.76e−6, maximum-likelihood
Table 1. Cohort overview.
Participants
Sex

SBS
19
7 (36.8%)
12 (63.2%)
34 (24–39)

Term
19
9 (47.4%)
10 (52.6%)
36 (33–37)

Preterm
18
10 (55.6%)
8 (44.4%)
26 (23–28)

Female
Male
Gestational age
[median (range)]
Bowel remaining (cm)
36.75 (25.63–
[median (IQR)]
58.5)
Ileocecal
Present
5 (26.3%)
Valve
Samples [n]
57
47
55
DOL at sampling
561 (394–867) 451 (298–623) 279 (79–422)
[median (IQR)]
Read depth (million)
5.17 (3.79–6.37)
4.83 (4.00–
4.30 (3.30–
[median (IQR)]
6.41)
5.13)
*SBS = Short bowel syndrome
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GLMM Tukey corrected for multiple comparisons,
Figure 1a). However, they did not statistically differ
from preterm infants during the first 2 years of life
(n = 112 samples, P = .998, maximum-likelihood
GLMM Tukey corrected for multiple comparisons,
Figure 1a). While alpha diversity positively corre
lated with increasing day of life in the preterm
cohort (n = 55, P = <0.001, maximum-likelihood
GLMM), the GM in SBS infants did not show
a similar trend (n = 57, P = .853, maximumlikelihood GLMM). To identify the main drivers
of microbiota diversity throughout the first 4
years of life in SBS, we further constructed SBS-
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specific GLMMs incorporating clinical metadata
(Methods, Supplementary Data Table 1).
Antibiotic exposure in the prior month negatively
correlated with microbiota alpha diversity (n = 49,
P = .042, maximum-likelihood GLMM FDR cor
rected for multiple comparisons, Figure 1b), while
male sex (n = 49, P = .483, maximum-likelihood
GLMM FDR corrected for multiple comparisons)
and presence of the ileocecal valve (n = 49, P = .456,
maximum-likelihood GLMM FDR corrected for
multiple comparisons) correlated with increased
alpha diversity but were not significant after multi
ple hypothesis correction. Further, microbiota

Figure 1. Taxonomic composition of the SBS microbiota compared to preterm and term controls. (a) Shannon diversity indices of the
gut microbiota of SBS patients (salmon), preterm (purple) and term controls (teal) by year of life (n = 159). Loess regression lines with 95%
confidence interval shading are drawn. All P-values are two-tailed, from longitudinal maximum-likelihood GLMMs Tukey-adjusted for multiple
comparisons. (b) Boxplot of Shannon diversity of SBS gut microbiota with or without exposure to antibiotics in the month prior to sampling
(n = 51, P = .042, longitudinal maximum-likelihood GLMM FDR corrected). (c) Principal Coordinate Analysis (PCoA) plot of species based on the
Bray–Curtis dissimilarity index for all samples (n = 159), colored by day of life. (d) Species enriched (salmon) or depleted (teal) in SBS patients
compared to term controls as determined via MaAsLin2. (Top) Number of species significantly depleted or enriched in SBS or term controls
plotted against determined binned effect sizes. (Bottom) Top 20% of species depleted or enriched in SBS patients compared to term controls
selected based on determined effect size.
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composition also has differed significantly among
the SBS, preterm and term cohorts (n = 159,
P = .002, repeat-measures PERMANOVA,
Figure 1c). While the day of life accounted for
a significant portion of the variance of the micro
biota composition in both the preterm and term
cohorts (n = 55 and n = 47, P = .001 and P = .001,
respectively, repeat-measures PERMANOVA,
Figure 1c), it did not have a similar effect in the
SBS cohort (n = 57, P = .311, repeat-measures
PERMANOVA, Table 2). Inter-individual variabil
ity accounted for the majority of variance in GM
composition in SBS patients (n = 57, P = .001,
repeat-measures PERMANOVA, Table 1), with
current exposure to enteral nutrition and race hav
ing smaller, non-significant effects (n = 57, P = .072
and P = .061, repeat-measures PERMANOVA,
Table 1). 57 and 21 species were identified to be
significantly enriched or depleted in SBS compared
to term or preterm infants, respectively (Figure 1d,
Supplementary Figure 1, 2, Supplementary Data
Tables 2, 3). Specifically, a variety of commensal
Ruminococcus, Bifidobacterium, Eubacterium, and
Clostridium species were depleted in SBS compared
to both preterm and term controls, respectively
(n = 104 and n = 112, respectively, qval = <0.05,
MaAsLin2, Figure 1d, Supplementary Figure 1, 2).
Conversely, multiple species with pathogenic
potential, including typical gut bacteria such as
Enterococcus faecalis as well as taxa not traditionally
considered constituents of the intestinal microbiota
such as Staphylococcus aureus or oral and respira
tory Streptococcus, were significantly enriched in
Table 2. Variance of microbiota composition explained by clin
ical variables determined via repeat measures PERMANOVA.

Gestational age at birth
Sex
Race
Ileocecal Valve (ICV)
Small bowel bacterial overgrowth
(SBBO)
Current antibiotics
Antibiotics in prior month
Length of bowel remaining
Day of life
Current enteral nutrition
Enteral nutrition ever
Current parenteral nutrition
Height percentile
Weight percentile
Participant
ALL

Variation
explained
2.12
2.99
4.45
9.24
5.62

P-value
0.814
0.391
0.061
0.244
0.466

4.15
3.69
3.74
2.12
5.46
4.96
6.32
2.38
2.65
45.76
51.15

0.71
0.777
0.587
0.311
0.072
0.153
0.444
0.137
0.193
0.001
0.215

stools of the SBS cohort (qval = <0.05, MaAsLin2,
Figure 1d, Supplementary Figure 1, 2).
To assess whether microbiota signatures found
in the first 4 years of life can also be observed later
in life, we analyzed the intestinal microbiota of
participant SBS 05 with samples collected in ado
lescence (average age at sampling 16.2 years). We
observed similarly high abundances of pathobionts
(E. coli, K. pneumoniae, Supplementary Figure 3),
which was associated with low Shannon diversity
values (<2), but not necessarily preceded by anti
biotic exposure.
The functional capacity of the SBS microbiome
varies compared to healthy controls

The GM serves critical functions for its host,
including digesting complex nutritional compo
nents to provide energy-rich metabolites for
healthy growth and development.21 Based on wideranging depletion of commensal species in SBS
compared to both preterm and term controls, we
hypothesized that key functional capabilities of the
microbiota are persistently altered in SBS. Indeed,
we identified significant changes in the functional
profiles of the GM in SBS compared to preterm and
term controls (n = 159, P < .01, repeat-measures
PERMANOVA, Figure 2a). A significant fraction of
the variance was explained by day of life in the
preterm and term cohorts, but not in SBS children
(n = 55, n = 47, and n = 57, P < .001, P < .001, and
P
=
.137,
respectively,
repeat-measures
PERMANOVA). We also have identified 199 meta
bolic pathways encoded by the microbiota persis
tently altered in SBS compared to term infants
throughout the first 4 years of life (n = 104,
qval = <0.05, MaAsLin2, Supplementary Data
Table 4). Functional aggregation of significantly
altered pathways indicated that pathways involved
in quinol and quinone biosynthesis (P = <0.001,
Fisher’s exact test, Benjamini–Hochberg corrected,
Figure 2b) were significantly enriched in the meta
bolic profile of the SBS microbiota, while pathways
involved in amino acid biosynthesis (P = .015,
Fisher’s exact test, Benjamini-Hochberg corrected)
and nucleoside and nucleotide biosynthesis
(P = .02, Fisher’s exact test, Benjamini–Hochberg
corrected) were significantly depleted. Specifically,
pathways involved in branched chain amino acids,
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Figure 2. Functional composition of the SBS microbiota throughout the first years of life. (a) Principal Coordinate Analysis (PCoA)
plot of functional pathway abundance based on the Bray–Curtis dissimilarity index for all samples (n = 159), colored by day of life. (b)
Pathways significantly enriched (salmon) or depleted (teal) in SBS patients aggregated into functional categories based on MetaCyc
hierarchy compared to term controls as determined via MaAsLin2. (Left and right) Number of pathways significantly depleted or
enriched in SBS or term controls within each functional category plotted against determined binned effect sizes. (Middle) Sum of all
depleted or enriched pathways within each functional category grouped by depletion and enrichment status in SBS patients compared
to term controls. (c) Amino acid synthesis or degradation pathways significantly enriched (salmon) or depleted (teal) in SBS patients
compared to term controls as determined via MaAsLin2.
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lysine, threonine, methionine, and histidine bio
synthesis were depleted in the microbiota of SBS
infants, while degradation pathways of various
amino acids were enriched in the microbiome of
SBS children (Figure 2c).
The resistome in SBS is persistently altered and
enriched for broad-spectrum ARGs

SBS patients are exposed to antibiotics throughout
childhood.15 As such exposures can enrich the
intestinal reservoir for ARGs (the “resistome”),16
we hypothesized that the resistomes of SBS infants
would be enriched compared to that of age-matched
preterm and term controls. We found increased
ARG abundance in the intestinal microbiomes of
SBS infants throughout the first years of life com
pared to term and preterm infants, respectively
(n = 104, and n = 112, P = <0.001 and P = .021,
maximum-likelihood GLMM Tukey corrected for
multiple comparisons, Figure 3a, Supplementary
Data Table 5). Current exposure to enteral nutrition
correlated with decreased ARG abundance (n = 51,
P = .011, maximum-likelihood GLMM, Figure 3b).
Conversely, resistome diversity (Shannon diversity)

and ARG richness did not differ significantly
between SBS patients and control cohorts (P > .895
for all comparisons, maximum-likelihood GLMM
Tukey corrected for multiple comparisons,
Supplementary Figure 4A, B). Resistome composi
tion differed significantly between SBS patients and
both preterm and term control cohorts throughout
infancy (n = 159, P = .001, repeat-measures
PERMANOVA, Figure 3c). Similar to the observed
effect of day of life on the taxonomic composition of
the GM, we found that age has explained
a significant portion of the resistome variance in
term and preterm children (n = 47 and n = 55,
P = .001 and P = .001, respectively, repeat-measures
PERMANOVA, Figure 1d), but not in SBS patients
(n = 57, P = .453, repeat-measures PERMANOVA,
Figure 3c). We aggregated ARGs by resistance class
to further characterize resistome differences between
cohorts. Abundance of four ARG classes correlated
significantly with SBS or control status (P < .05, max
imum-likelihood GLMM Tukey corrected for multi
ple comparisons, Supplementary Figures 5A-D). SBS
status was positively correlated with the abundance
of broad-spectrum efflux pump ARGs compared to
the term cohort, while lincosamide ARGs were

Figure 3. Resistome composition in SBS throughout the first years of life. (a) ARG abundance measured in RPKM within the
microbiome of SBS patients (salmon), preterm (purple) and term controls (teal) by year of life (n = 159). Loess regression lines with 95%
confidence interval shading are drawn. All P-values are two-tailed, from longitudinal maximum-likelihood GLMMs Tukey-adjusted for
multiple comparisons. (b) Boxplot of ARG abundance measured in RPKM within the microbiome of SBS patients with or without
exposure to enteral nutrition at sampling (n = 51, P = .011, longitudinal maximum-likelihood GLMM). (c) Principal Coordinate Analysis
(PCoA) plot of ARG abundance profiles based on the Bray–Curtis dissimilarity index for all samples (n = 159), colored by day of life.
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negatively correlated with SBS status. Resistance
modulator ARGs were significantly more abundant,
while fosfomycin ARGs were depleted in SBS com
pared to preterm infants.
Persistent gut pathogens can cause recurrent
bacteremia

The gut is increasingly recognized as the predissemination habitat of bacteria that cause
BSI.18–20 As we observed enrichment of patho
bionts in the intestinal tract of SBS patients, we
hypothesized that intestinal pathobionts may
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cause bacteremia in patients with SBS. To investi
gate this hypothesis, we performed whole-genome
sequencing of 13 BSI isolates from the SBS cohort
(Supplementary Data Table 6). We compared the
phylogenetic relatedness of BSI isolates to stool
strains from corresponding patients, as well as
unrelated terms and preterm infants recruited in
the same hospital system. We identified 3 BSI
isolates (two E. faecalis and 1 K. pneumoniae)
that belonged to the same strain (1–6 SNPs and
128 SNPs, respectively, Supplementary Data Table
7) as species representatives recovered from stools
(Figure 4a, b). Interestingly, in one participant

Figure 4. Gut-persisting pathobionts can cause repeated episodes of BSI in SBS. (a) E. faecalis persists in patient SBS 07 causing
two BSI over 3 years of life. (Top) Relative abundance of E. faecalis in stools (red) by year of life. Other species are depicted in gray.
Schematic of sample collection and BSI events is shown on top. (Bottom) Phylogenetic relatedness of BSI isolates and metagenomic
strains based on core SNPs as assessed by StrainSifter. Branch tip colors indicate BSI isolates (red), SBS (brown) and preterm (peach), or
term (teal) stools. (b) K. pneumoniae found in a stool of patient SBS 01 concurrently causes a BSI. (Top) Relative abundance of
K. pneumoniae in stools (green) by year of life. Other species are depicted in gray. Schematic of sample collection and BSI events is
shown on top. (Bottom) Phylogenetic relatedness of BSI isolates and metagenomic strains based on core SNPs as assessed by
StrainSifter. Branch tip colors indicate BSI isolates (red), SBS (brown) and preterm (peach), or term (teal) stools.
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(SBS 07), a strain of E. faecalis was found in the
stool prior to any BSIs and persisted in the stool
for ~2.7 years of subsequent sampling. While the
E. faecalis abundance over this time remained low,
averaging 4.99%, this strain caused two episodes of
BSI separated by ~8.5 months (Figure 4a).
Similarly, we found that a strain of
K. pneumoniae causing a BSI in participant SBS
01 was found at the time of the infection in the gut
(sample SBS 01 007). However, a second episode
of BSI experienced by the participant ~7.7 months
earlier was caused by an unrelated strain of
K. pneumoniae and a third unrelated strain was
found to dominate a previous stool specimen
(Figure 4b, Supplementary Data Table 7).
Discussion

Providing adequate nutrition for growth and ulti
mately achieving enteral autonomy by promoting
intestinal adaptation are the goals of pediatric SBS
management.15 Intestinal microbiota may contri
bute to intestinal adaptation either directly or by
producing host-interactive metabolites that stimu
late intestinal immune development and enterocyte
proliferation.22,23 Prior studies have largely
employed 16S rRNA gene sequencing, which allows
taxonomic description, but is inadequate for char
acterizing the metabolic potential of the microbiota
in SBS. Moreover, characterization of SBS micro
biota has not been supported by longitudinal sam
pling with appropriate age-matched controls,
a prerequisite for robust interrogation of the pedia
tric intestinal microbiome, which changes rapidly
in the first years of life.24 Here, we mitigate these
issues by analyzing a longitudinally-sampled cohort
of pediatric SBS patients. We comprehensively
evaluated taxonomic, functional, and resistome
correlates of SBS by comparing them to two agematched cohorts of term and preterm infants
recruited in the same hospital system.
Consistent with previous reports,10–12,14 we find
that GM diversity is decreased in SBS compared to
term children and that this signature persists
throughout the first four years of life. We identify
antibiotic exposure as the main driver of dimin
ished GM diversity in SBS. Interestingly, early life
microbiota diversity between preterm and SBS
infants did not differ significantly in our analysis.

This finding may reflect the similarly high rate of
antibiotic exposure early in life.16 However, while
microbiota diversity increased with day of life in
preterm infants with intact intestinal anatomy, an
effect attributed to reduced antibiotic exposure
after hospital discharge,17 such a correlation was
not observed in SBS patients. Overall, our data
suggest that pediatric SBS patients do not undergo
GM maturation common to both term and preterm
infants during the first two years of life.24,25 The
decreased diversity and lack of GM maturation
likely reflect that both hospitalizations and antibio
tic exposures remain substantial beyond infancy in
children with SBS, because of their increased risk of
serious bacterial infections secondary to BSI and
SBBO.7 This underscores the importance of con
tinued studies on mechanisms of intestinal adapta
tion. Sampling of a 16-year-old SBS participant
further suggests that this trend may continue into
adolescence, an important question that should be
investigated further.
Functional profiling of SBS microbiota has been
limited by sample size and the availability of appro
priate age-matched controls,14 but is critical to our
understanding of the role of microbiota in intest
inal adaptation and immune maturation.23 Here,
we show that the altered taxonomic composition
of the intestinal microbiota in SBS is accompanied
by alterations of the encoded metabolic repertoire
compared to healthy-term children. Key biosyn
thetic functions provided by healthy microbiota,
including synthesis of vitamins, nucleosides/
nucleotides, and amino acids were persistently
depleted in pediatric SBS microbiota. Microbiotaderived B vitamins such as folate and thiamine play
key roles in diverse processes, such as DNA methy
lation and intestinal adaptation.23,26,27 Similarly,
the intestinal microbiota influences gut concentra
tion of branched-chain amino acids, which are
beneficial for gut homeostasis, intestinal immunity,
barrier function and growth.28–30 Depletion of
these key biosynthetic pathways in SBS may con
tribute to chronic malabsorption and thereby
impaired growth.15 Conversely, enrichment of
fatty acid and lipid biosynthetic pathways may con
tribute to colonic inflammation observed in
SBS.22,31 We also found that intestinally-derived
lipids enriched in the SBS cohort, including palmi
tate, lipopolysaccharide, and oleate, may contribute
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to intestinal inflammation and mucosal injury.32–34
Furthermore, we observed wide-ranging alterations
of central microbiota functionalities, including
enrichment of aerobic respiration, gluconeogenesis,
glycolysis, TCA cycle, heme biosynthesis, and fer
mentation pathways, reflective of the altered phy
siological conditions in the SBS intestine. Further
cohort studies are necessary to resolve the func
tional impact of these alterations on host physiol
ogy and their association with intestinal adaptation.
As antibiotic exposure shapes resistome enrich
ment and composition,16,17 we hypothesized that
frequent antibiotic exposure in SBS patients would
diversify and enrich the resistome. Indeed, we
observed an increased abundance of ARGs and
restructuring of the resistome composition in SBS
patients compared to preterm and term cohorts.
However, we did not find the resistome to be
more diverse or enriched for a greater quantity of
unique ARGs compared to the preterm and term
cohorts. This indicates that an increased abundance
of pathobionts, previously associated with
increased ARG abundance,35 is likely the main
determinant of the increased abundance of ARGs
in SBS. Current enteral nutrition, associated with
altered taxonomic composition of the SBS micro
biota, was negatively correlated with ARG abun
dance, supporting the idea that taxonomy and
resistome in SBS are connected in early life.
Intestinal pathobiont presence has been identi
fied as a source for BSI in multiple vulnerable
patient cohorts, including preterm infants.18–20 It
has been hypothesized that the intestinal micro
biota may similarly be the source of BSI common
in SBS patients, as there is a greater abundance of
pathobionts including E. coli, E. faecalis, and
K. pneumoniae in their intestinal microbiota com
pared to healthy controls.9,36 Previous research has
shown that the GM of SBS patients with BSI is
marked by a significantly increased pathobiont
abundance and lower alpha diversity compared to
SBS patients without BSI.11 Here, we combine
whole-genome sequencing of SBS patients’ BSI iso
lates and culture-enriched metagenomics of stool
specimens to provide evidence that gut-derived
pathobionts can cause repeated BSI throughout
early life and persist for years despite SBBO pro
phylaxis and treatment with antimicrobial therapy.
We found that these pathobionts are frequently
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minority constituents of the GM and further inves
tigation is needed to determine if intestinal blooms
prior to infectious episodes are required to facilitate
bacterial translocation into the bloodstream, as
observed in other gut-derived infections.37 Our
demonstration of persistence of gut bacteria that
cause recurrent episodes of BSIs suggests that gut
colonization with bacteria with invasive potential
may not be transient. Patients with clinical symp
toms suggestive of SBBO are typically treated with
antibiotics to suppress strict and facultative
anaerobes,38 which may decrease chronic diarrhea
and malabsorption. However, our study found
other gut bacteria not typically targeted in SBBO
treatment that caused BSI, possibly resulting from
gut barrier dysfunction in SBS. Unfortunately,
these bacteria are enriched in genes encoding resis
tance to parenteral antibiotics used for treatment
and prophylaxis of BSI and SBBO. These findings
highlight the complexity of decision-making sur
rounding antibiotic use in this patient population.
Given the detrimental effects on microbiota com
position and function, antibiotic stewardship is cri
tical not only for optimizing intestinal adaptation
in the pediatric SBS patient population, but also for
decreasing risk of serious infections and antibiotic
resistance.
Though it is the largest longitudinal sample
collection from SBS patients reported to date,
our study was still limited by sample availability.
Thus, our finding that representatives of only 3/13
strains causing a BSI event could be trackedto the
intestine may underestimate the true burden of
gut-derived BSI events, as fecal samples collected
within days of BSI onset were often unavailable.
Future studies with more granular sampling
schemes should aim to assess the burden of gutderived BSI events quantitatively. The severity and
consequences of surgical intervention in SBS can
vary significantly between patients and success of
intestinal adaptation in childhood is dependent on
a multitude of factors, including remaining bowel
length, nutritional status, bowel function, antibio
tic exposure, and presence of ICV and colon.15
Given this variability in the pediatric SBS popula
tion, future studies must rely on large, welldefined patient cohorts to comprehensively
address the impact of all potentially relevant fac
tors on the intestinal microbiota and intestinal
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adaptation. Large, prospective cohort studies,
similar to those reported for inflammatory bowel
disease,39 combining high-resolution metabolo
mics, lipidomics, and metagenomics are warranted
for detailing the role of the microbiota in postsurgical intestinal adaptation in SBS. Nonetheless,
our findings support the important and enduring
effect of intestinal taxonomic changes on meta
bolic pathways in SBS patients. Additionally, our
finding of increased gut carriage of pathobionts
and altered antibiotic resistance genes driven by
antibiotic exposure underscore the necessity of
judicious antibiotic use in this high-risk
population.

Methods
Study design

Patients with SBS were recruited from the Pediatric
Intestinal Rehabilitation Clinic at St. Louis
Children’s Hospital (SLCH). SBS was defined as
parenteral nutrition requirement >90 days follow
ing the initial bowel resection. Patients aged
17 years old and younger were included in the
study if they were diagnosed with SBS at <2 years
of life and excluded if they had extra-intestinal
congenital anomalies or if they underwent liver or
intestinal transplant. Stools were collected quarterly
when possible, either from a diaper or a collection
receptacle placed in the toilet prior to spontaneous
stooling. Stool were immediately stored at −80°C
until analyzed.
Clinical and demographic data were obtained
from electronic medical records. Remnant short
bowel length and presence of ileocecal valve were
extracted from the surgical operative reports or
intestinal
rehabilitation
clinic
notes.
Anthropomorphic measurements found in electro
nic medical records were obtained on the day of, or
within a month of, stool collection. For participants
under two years old, percentiles for weight and
length were based on the World Health
Organization (WHO) reference values after cor
recting for gestational age. For samples obtained
when children were 2 years or older, the US
Centers for Disease Control and Prevention
(CDC) growth chart were used. Each course of
intravenous antibiotic treatment was obtained

from medication histories recorded during hospi
talizations and oral antibiotic treatment obtained
from intestinal rehabilitation clinic notes. This
study was approved by Washington University’s
IRB (201912067).
Preterm and term controls were selected from
two previously published studies.16,17 All of the
preterm and term samples and metadata were col
lected as part of the Neonatal Microbiome and
Necrotizing Enterocolitis Study (P.I.T. and B.B.
W.) or the St Louis Neonatal Microbiome
Initiative (B.B.W. and P.I.T.) at Washington
University School of Medicine and approved by
the IRB (201105492 and 201104267, respectively).
Samples were obtained from infants after parents
provided informed consent. For each SBS patient,
matching controls were selected based on similarity
of age-distribution at sample collection points.
Metagenomic DNA extraction

Metagenomic DNA was extracted from approxi
mately 100 mg stool using the PowerSoil DNA
Isolation Kit (Qiagen) following the manufac
turer’s protocol, except that samples were
mechanically lysed for two rounds of two min
utes each using a Mini-Beadbeater-24 (Biospec
Products)
at
2,500
oscillations
min−1.
Metagenomic DNA was quantified using Qubit
(Invitrogen) and stored at −20°C.
BSI isolate collection and DNA extraction

Glycerol stocks of isolates cultured from SBS
patients during hospitalizations for BSI at
SLCH, St. Louis, Missouri, were used for this
study. 1 μL from each specimen was plated to
sheep’s blood agar plates (Hardy Diagnostics)
using a 1 μL calibrated loop and incubated at
37°C for 24 hours. Genomic DNA was extracted
using the Bacteremia DNA Extraction Kit
(Qiagen) following the manufacturer’s protocol.
Selective culturing of stools

Stool specimens from SBS patients with available BSI
isolates were selected for selective culturing if the BSI
causative species was as follows (1) detected in the
metagenomic dataset and (2) was present at <5%
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relative abundance. The following media were used
for selective enrichment of BSI causing pathogens:
E. coli – MacConkey agar (Hardy Diagnostics),
Klebsiella sp. – Klebsiella ChromoSelect Selective
Agar
(Millipore
Sigma),
E.
faecalis
– m-Enterococcus agar, modified (Millipore Sigma),
S. aureus and S. epidermidis – Aureus ChromoSelect
Agar (Millipore Sigma). Approximately 5 mg of stool
material were plated onto the respective culture
media, which were incubated for 24–48 hours
(37°C). In cases of positive growth, plates were har
vested and metagenomic DNA was extracted using
the PowerSoilPro DNA Isolation Kit (Qiagen).
Library preparation, sequencing, and quality
filtering

Sequencing libraries from both isolate gDNA and
metagenomic DNA were prepared using the
Nextera kit (Illumina). Libraries were pooled and
shotgun sequenced (2x150 bp) to a pre-determined
depth of ~1.5 million reads (BSI isolates – 1.55
(1.29–1.77) [median IQR]) or ~5 million reads
(fecal metagenomes – 5.17 (3.79–6.37) million
reads [median (IQR)]) on the NextSeq 500
HighOutput platform (Illumina). For BSI-strain
tracking, selected stools were sequenced to
a coverage that facilitated ~50x genome coverage
of the species of interest (8.54 (6.52–12.84) million
reads [median (IQR)]), calculated based on relative
abundance as determined from previous medium
depth metagenomic sequencing. Selectively cul
tured isolates were sequenced to a depth of
~1.5 million reads (1.68 (1.47–2.21) million reads
[median (IQR)]). The resulting reads were trimmed
of adapters using Trimmomatic v.36 (parameters:
LEADING:10
TRAILING:10
SLIDINGWINDOW:4:15
MINLEN:60)
and
depleted of human read contamination using
DeconSeq
v.4.3
(default
parameters).40,41
Rarefaction analysis was performed for both taxo
nomic profiles (diversity/richness) and antibiotic
resistance genes (diversity/richness), confirming
appropriate coverage at the predetermined sequen
cing depth (Supplementary Figure 6). Rarefaction
was used to establish appropriate coverage of the
microbiome using the predetermined sequencing
depth, and subsampled metagenomes were not
used for analyses.
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Microbiome and statistical analysis

Quality filtered paired-end metagenomic reads from
all cohorts were used to access microbial taxa rela
tive abundance using MetaPhlAn2 v.2.6.0 (default
parameters) and functional profiles of the intestinal
microbiota using HumaNn2 v.2.8.1 (default
parameters).42,43 Resistance gene abundance was
determined using ShortBRED v.0.9.4 using marker
sequences build on the CARD and NCBI AMR
databases (default parameters).44 Statistical analysis
and visualization were conducted in R v.3.6.3 using
the ggplot2, ggpubr, VEGAN, BiodiversityR, ape,
lme4, nlme, pheatmap, purr, dplyr, labdsv, reshape,
ggpmisc, rowr, rsample, permute, rcompanion,
multcomp, and MaAsLin2 packages.
α- and β-microbiota diversity were calculated
using VEGAN. Repeat measures permutational ana
lysis of variance (PERMANOVA) was implemented
taking advantage of a previously developed custom
script.39 Patient ID was included as a mandatory
blocking
factor
in
all
repeat
measure
PERMANOVA. Variance explained by each clinical
variable was calculated independently to avoid issues
of variable ordering in the model formula. To
account for repeat measures, permutations were per
formed blocked within participant for variables chan
ging over time. For constant variables (e.g., length of
bowel remaining, gestational age at birth), permuta
tions were performed across participants. To deter
mine variance explained by inter-individual
variation, permutations were performed freely.
Maximum-likelihood generalized linear-mixed
models (GLMMs) were implemented using the
nlme package (lme function) or the MaAsLin2
package.45 Samples with missing data were
excluded before analysis. All longitudinal GLMMs
included patient ID as a mandatory random effect.
To determine enriched/depleted taxa and func
tions, MaAsLin2 was run on relative abundance
patterns of species or functions using default para
meters. To assess between cohort differences for
other features (e.g., α-diversity), all other model
formulas followed the general structure:
feature ~ cohort*day of life + (1|Patient)
To assess the impact of clinical covariates on
outcome of interest in the SBS cohort, variables
were pre-screened for inclusion in a first (naïve)
model as described.46 Following naïve model
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fitting, back-fitting was performed using the step()
function. The best model from the set of back fitted
models was selected based on model AIC values.
P-value were corrected for multiple comparisons
using Tukey’s method in the glht() function.
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BSI isolate strain-tracking

Draft genomes of BSI isolates were assembled using
SPAdes v.3.11.0 (parameters: -k 21,33,55,77 -careful)
.47 The resulting scaffolds.fasta files were used for
analysis. The quality of draft genomes were assessed
by calculating assembly statistics using QUAST
v5.0.2 and checkM v.1.0.13.48,49 Bowtie indices
were constructed and reads from metagenomic sam
ples and isolates were aligned to BSI isolate genomes
using Bowtie2 v.2.3.5 (parameters: – very-sensitive –
n-ceil 0,0.01).50 Pairwise core single nucleotide poly
morphism (SNP) distances between BSI isolates and
metagenomic strains were determined using the
strainsifter workflow.19 Core SNPs were determined
using mafft v. 7.471 (default parameters) and muscle
v.3.8.1551 (default parameters) and phylogenetic
trees were constructed using fasttree v.2.1.10 (para
meter: -nt).
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